Osteoarthritis — Wear, Tear, and Much More Than That
Osteoarthritis (OA) is the most common form of arthritis, affecting roughly 32.5 million American adults. It was traditionally described as "wear and tear" — mechanical degradation of the cartilage cushioning your joints. But we now know it is far more complex. OA involves active inflammation, abnormal bone remodeling, changes in the joint lining (synovium), and alterations in the biomechanics of the entire joint.
Healthy cartilage is smooth, slippery, and resilient — it absorbs shock and allows bones to glide smoothly against each other. In OA, the cartilage breaks down — it becomes thin, rough, and eventually exposes the underlying bone. Bone-on-bone contact causes pain, inflammation, bone spurs (osteophytes), and progressive loss of joint function. But cartilage breakdown is only part of the story. The surrounding bone changes shape (sclerosis, osteophytes), the joint lining becomes inflamed, the muscles around the joint weaken, and the joint mechanics alter — creating a cascade of dysfunction.
The most commonly affected joints are knees (the most frequent), hips, hands (particularly the base of the thumb and finger joints), spine, and feet. Risk factors include age (cartilage repair capacity declines), obesity (every extra pound adds roughly 4 pounds of force across the knee with each step), prior joint injury (a torn meniscus or ACL tear increases OA risk by 4 to 6 times), genetics, female sex (higher risk after menopause), and occupations requiring repetitive joint loading.
A 57-year-old former soccer player had been told he had "bone on bone" in his right knee and his only option was joint replacement. A sports medicine physician prescribed a structured exercise program focused on quadriceps strengthening, weight loss, and activity modification. After 4 months, his pain decreased by 60 percent and he postponed surgery. "Everyone told me exercise would make it worse," he said. "It was the opposite."
Rheumatoid Arthritis — When Your Immune System Attacks Your Joints
Rheumatoid arthritis (RA) is fundamentally different from OA. It is an autoimmune disease where the immune system attacks the synovium (joint lining), causing inflammation that destroys cartilage, bone, and surrounding tissue. It is systemic — meaning it affects the whole body, not just joints. Fatigue, fever, and weight loss often accompany joint symptoms.
RA typically affects joints symmetrically (both wrists, both hands, both knees) and preferentially targets the small joints — fingers, wrists, and toes. Morning stiffness lasting more than 30 minutes is a hallmark — in OA, morning stiffness typically resolves within 15 minutes. A study in Arthritis and Rheumatism found that without treatment, 50 percent of RA patients had significant work disability within 10 years, and irreversible joint erosion began within the first 2 years of disease in most patients.
The urgency of early treatment cannot be overstated. A landmark concept called the "window of opportunity" demonstrates that aggressive treatment started within the first 3 to 6 months of symptoms produces dramatically better outcomes than delayed treatment. A study in the Annals of Rheumatic Diseases found that patients treated within this window were 33 percent more likely to achieve remission. If you have symmetrical joint swelling, prolonged morning stiffness, and fatigue — see a rheumatologist urgently, not in 3 months.
Treatment — Osteoarthritis
Exercise is the most effective non-surgical treatment for OA — as effective as NSAIDs for pain with better long-term outcomes. A meta-analysis in the British Journal of Sports Medicine found that exercise reduced knee OA pain by 30 to 40 percent and improved function by 30 percent. Strengthening the muscles around the joint (particularly the quadriceps for knee OA) offloads the damaged cartilage. Low-impact aerobic exercise (walking, cycling, swimming) reduces stiffness and improves overall function. Flexibility exercises maintain range of motion.
Weight loss: For overweight patients with knee OA, losing 10 percent of body weight reduces pain by 50 percent according to the IDEA trial. Combined with exercise, this is the closest thing to a disease-modifying treatment available for OA. Physical therapy: Targeted strengthening, manual therapy, and movement retraining reduce pain and improve function. Walking aids: A cane used in the opposite hand reduces knee joint loading by 10 to 20 percent.
Medications: Acetaminophen and NSAIDs for pain (see our ibuprofen vs acetaminophen guide). Topical NSAIDs (diclofenac gel) are as effective as oral NSAIDs for knee and hand OA with fewer systemic side effects. Intra-articular corticosteroid injections provide 4 to 8 weeks of relief. Hyaluronic acid injections have modest evidence. Duloxetine is FDA-approved for OA pain through central pain modulation.
Joint replacement: For severe OA not responding to conservative measures, total joint replacement is one of the most successful surgeries in medicine. A study in The Lancet found that 82 percent of total knee replacement patients reported good to excellent outcomes at 25 years. Over 1 million knee and hip replacements are performed annually in the US.
Treatment — Rheumatoid Arthritis
RA treatment follows a treat-to-target strategy: the goal is remission or low disease activity, assessed regularly with objective measures, and treatment is escalated until the target is reached.
Methotrexate is the anchor drug — first-line for nearly all RA patients. It reduces inflammation, slows joint destruction, and is well-tolerated at low doses (7.5 to 25mg weekly). A study in the New England Journal of Medicine found that early methotrexate reduced joint erosion progression by 65 percent compared to delayed treatment. Taken with folic acid to reduce side effects.
Biologic therapies — for patients not achieving target with methotrexate alone. TNF inhibitors (adalimumab, etanercept, infliximab) were the first biologics and remain highly effective. A meta-analysis found that TNF inhibitors plus methotrexate achieved remission in 28 to 34 percent of patients. Newer targeted therapies include IL-6 inhibitors (tocilizumab), T-cell costimulation blockers (abatacept), B-cell depletion (rituximab), and JAK inhibitors (tofacitinib, baricitinib — oral pills rather than injections).
A 35-year-old software engineer noticed swollen, painful finger joints that made typing difficult. Morning stiffness lasted 2 hours. Her primary care doctor ran blood tests — rheumatoid factor and anti-CCP antibodies were positive. She was referred to a rheumatologist who started methotrexate within 2 weeks of the referral. Within 3 months, her swelling resolved and she was typing pain-free. "If I had waited a year to see someone, my joints could have been damaged permanently," she said. "Early treatment saved my hands."